E P H K

E P H K is a pharmaceutical importer and buyer based in Hungary, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in Hungary's pharmaceutical distribution network, ensuring the availability of essential medications across the country. While specific details about its headquarters and parent company are not publicly disclosed, E P H K's operations are integral to the Hungarian healthcare system, facilitating the importation and distribution of critical pharmaceutical products.

E P H K's distribution network encompasses multiple warehouse locations strategically situated to optimize logistics and ensure timely delivery of pharmaceutical products throughout Hungary. The company's logistics capabilities are robust, enabling efficient handling, storage, and transportation of a diverse range of medications. Geographically, E P H K's coverage extends across Hungary, with potential outreach to neighboring countries, thereby enhancing the accessibility of imported pharmaceutical products to a broader European market.

Within Hungary's pharmaceutical supply chain, E P H K functions primarily as an importer and distributor of finished pharmaceutical formulations. The company sources a variety of medications from international suppliers, including a significant volume from India, and facilitates their entry into the Hungarian market. By doing so, E P H K ensures that a wide array of pharmaceutical products is available to meet the needs of healthcare providers and patients across the country.

E P H K's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.5 million USD from India over 33 shipments, all sourced from a single supplier, Venus Remedies Limited. This single-source dependency may pose risks related to supply chain disruptions, such as potential delays or quality control issues. However, the consistent volume and frequency of shipments suggest a stable and well-established relationship between E P H K and Venus Remedies Limited, indicating a strategic choice to maintain a reliable supply chain.

E P H K's supply chain resilience is closely tied to its exclusive partnership with Venus Remedies Limited. The lack of backup suppliers and the concentration on a single supplier may expose the company to risks associated with supply chain disruptions. Additionally, the limited diversity in imported formulations, with 59 unique formulations, could impact the company's ability to adapt to changing market demands. The resilience of the supply chain is further influenced by the shipping routes and the regulatory compliance of Venus Remedies Limited, which must adhere to international standards to ensure uninterrupted supply.

E P H K's sourcing pattern, characterized by a concentrated supplier base and limited product diversity, has significant strategic implications. The company's competitive position may be affected by its dependency on a single supplier, potentially limiting its ability to negotiate better terms or diversify its product offerings. For Indian exporters seeking to become alternative suppliers, this presents an opportunity to introduce a broader range of products and establish relationships with E P H K, thereby enhancing the company's supply chain resilience and market competitiveness.

In Hungary, the National Institute of Pharmacy and Nutrition (OGYÉI) serves as the primary regulatory authority overseeing pharmaceutical imports. The regulatory framework governing pharmaceutical imports is primarily defined by the Medicines Thrift Act (Act XCVIII of 2006) and the Medicinal Products Act (Act XCV of 2000). These acts implement European Union directives and international regulations, establishing comprehensive guidelines for the importation, distribution, and marketing of medicinal products in Hungary. The Medicines Thrift Act focuses on the reliable and economically feasible supply of medicinal products, while the Medicinal Products Act addresses the registration, clinical trials, and wholesale distribution of medicines. (cms.law)

Import licensing in Hungary requires compliance with Good Manufacturing Practice (GMP) standards, which are recognized by the European Union and the World Health Organization. Importers must obtain the necessary licenses from OGYÉI, ensuring that imported pharmaceutical products meet stringent quality and safety standards. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of medicinal products, ensuring that all stages of the pharmaceutical supply chain adhere to regulatory requirements. (ogyei.gov.hu)

Pharmaceutical products imported into Hungary must undergo batch testing and meet stability requirements to ensure their safety and efficacy. Labeling must be in Hungarian, providing clear and accurate information about the product's name, active ingredients, dosage instructions, and any special warnings or precautions. Serialization mandates are in place to prevent counterfeit products and ensure traceability throughout the supply chain. These requirements are enforced by OGYÉI to maintain the integrity of the pharmaceutical market in Hungary. (ogyei.gov.hu)

Between 2024 and 2026, Hungary implemented several regulatory changes affecting pharmaceutical imports. These included updates to the Medicines Thrift Act and the Medicinal Products Act to align with European Union directives, enhancing the efficiency and transparency of the importation process. Additionally, new rules of conduct were introduced to increase transparency in relationships between the pharmaceutical industry and healthcare organizations, providers, and patient organizations. These changes aim to improve the regulatory environment for pharmaceutical imports and distribution in Hungary.

E P H K's focus on importing advanced antibiotics and oncology medications aligns with the growing demand for specialized treatments in Hungary. The substantial import value of meropenem and ceftazidime indicates a strategic emphasis on addressing critical healthcare needs in the country. The inclusion of oncology medications like bleomycin and topotecan reflects a commitment to providing comprehensive treatment options for cancer patients. This product strategy positions E P H K as a key player in supplying essential and specialized pharmaceutical products to the Hungarian market.

E P H K's sourcing strategy is centered on importing generic drugs from India, focusing on finished pharmaceutical formulations. The company's preference for formulations that meet EU GMP standards ensures compliance with regulatory requirements and maintains product quality. India's established pharmaceutical manufacturing capabilities and cost-effectiveness make it a strategic partner for E P H K, enabling the company to offer a diverse range of medications to the Hungarian market.

E P H K serves a critical segment of the Hungarian pharmaceutical market by supplying advanced antibiotics and oncology medications. The company's product mix caters to both hospital and retail pharmacy sectors, ensuring that healthcare providers and patients have access to essential and specialized treatments. By focusing on these therapeutic areas, E P H K positions itself as a key supplier of critical medications, contributing to the overall health and well-being of the Hungarian population.

There is a realistic opportunity for new Indian suppliers to collaborate with E P H K, especially in the oncology segment, where the company imports a limited number of products. Introducing a broader range of oncology medications could enhance E P H K's product portfolio and meet the growing demand for cancer treatments in Hungary. Additionally, diversifying the supplier base could mitigate risks associated with single-source dependency and strengthen the resilience of E P H K's supply chain.

Indian exporters seeking to supply E P H K and the Hungarian market must ensure that their products comply with EU GMP standards and obtain the necessary marketing authorizations from OGYÉI. Products must undergo batch testing and meet stability requirements to ensure safety and efficacy. Labeling must be in Hungarian, providing clear and accurate information about the product. Additionally, exporters must adhere to serialization mandates to prevent counterfeit products and ensure traceability throughout the supply chain.

Indian exporters should initiate contact with E P H K by presenting their product portfolio and demonstrating compliance with EU GMP standards. Participating in tenders and engaging in discussions about regulatory filing strategies can facilitate entry into the Hungarian market. Understanding the regulatory framework and ensuring that products meet all necessary requirements will streamline the approval process. Establishing a partnership with E P H K can lead to a mutually beneficial relationship, expanding market reach and enhancing the availability of essential pharmaceutical products in Hungary.